Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Teva
Deloitte
Queensland Health
Moodys
Covington
Cipla
AstraZeneca
Mallinckrodt

Generated: September 20, 2018

DrugPatentWatch Database Preview

Relypsa Inc Company Profile

« Back to Dashboard

What is the competitive landscape for RELYPSA INC, and when can generic versions of RELYPSA INC drugs launch?

RELYPSA INC has one approved drug.

There are eleven US patents protecting RELYPSA INC drugs.

Summary for Relypsa Inc
US Patents:11
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Relypsa Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes No 8,287,847 ➤ Try a Free Trial ➤ Try a Free Trial
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No 9,925,212 ➤ Try a Free Trial ➤ Try a Free Trial
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 RX Yes Yes 8,147,873 ➤ Try a Free Trial Y ➤ Try a Free Trial
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No 8,147,873 ➤ Try a Free Trial Y ➤ Try a Free Trial
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 RX Yes Yes 9,925,212 ➤ Try a Free Trial ➤ Try a Free Trial
Relypsa Inc VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes No 7,556,799 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for Relypsa Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,429,394 Ion binding compositions ➤ Try a Free Trial
8,192,758 Ion binding compositions ➤ Try a Free Trial
7,854,924 Methods and compositions for treatment of ion imbalances ➤ Try a Free Trial
7,776,319 Methods and compositions for treatment of ion imbalances ➤ Try a Free Trial
8,445,014 Ion binding compositions ➤ Try a Free Trial
7,488,495 Ion binding polymers and uses thereof ➤ Try a Free Trial
8,409,561 Methods and compositions for treatment of ion imbalances ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Relypsa Inc Drugs

Supplementary Protection Certificates for Relypsa Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2018 00003 Denmark ➤ Try a Free Trial PRODUCT NAME: PATIROMER AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179 20170721
2018 00006 Denmark ➤ Try a Free Trial PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721
2018004 Lithuania ➤ Try a Free Trial PRODUCT NAME: PATIROMERO, SORBITOLIO IR KALCIO KOMPLEKSAS IR JO DRUSKOS; REGISTRATION NO/DATE: EU/1/17/1179 20170719
0924 Netherlands ➤ Try a Free Trial PRODUCT NAME: PATIROMER EN ALLE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/17/1179/001-009 20170721
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
US Department of Justice
Teva
Fuji
Baxter
McKinsey
Citi
Medtronic
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.